An Abbott Laboratories processing plant in Sturgis, Mich being investigated for cases of infant illness is being allowed to release some product that was processed before it was shut down.
Certain goods designed for infants and people with specific medical issues will be given out for free.
Abbott officials claimed they're doing it at the FDA's request to help with shortages of these specialty feeding items.
After a recall of Similac infant formula and other products in February, the Sturgis plant was forced to shut down. Cronobacter bacteria had infected many infants, one of whom died; cronobacter was identified in their systems and the formula they had drunk. Cronobacter bacteria were discovered in the factory during an inspection.
However, further examination revealed that the cronobacter strain that caused the infections was not the same as the one detected in the plant and that no food-contact surfaces had been contaminated.
On a case-by-case basis, Abbott is issuing cases of a nutrition supplement for people with uncommon metabolic diseases and others. The corporation stated that it is doing so at the FDA's request to assist reduce shortages.


Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy
Trump Backs Review of U.S. Childhood Vaccine Schedule After Hepatitis B Policy Change
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
Asian Stocks Edge Higher as Tech Recovers, U.S. Economic Uncertainty Caps Gains
U.S. Stock Futures Slip After CPI-Fueled Rally as Markets Weigh Economic Uncertainty
U.S. and Rwanda Sign $228 Million Health Partnership to Boost Self-Reliance
FDA Says No Black Box Warning Planned for COVID-19 Vaccines Despite Safety Debate
Japan Exports to U.S. Rebound in November as Tariff Impact Eases, Boosting BOJ Rate Hike Expectations
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Cogent Biosciences Soars 120% on Breakthrough Phase 3 Results for Bezuclastinib in GIST Treatment
U.S. Stock Futures Edge Higher as Micron Earnings Boost AI Sentiment Ahead of CPI Data
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions
Obamacare Premiums Set to Double in 2026 as Subsidy Expiration Looms Amid U.S. Shutdown
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Trump Signs Executive Order to Boost AI Research in Childhood Cancer
Asian Stocks Slide as AI Spending Fears and Global Central Bank Decisions Weigh on Markets 



